Skip to main content
main-content

Zeitschrift

Breast Cancer Research

Breast Cancer Research 1/2005

Sonderheft 1/2005

VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Inhaltsverzeichnis ( 43 Artikel )

01.05.2005 | Oral presentation | Sonderheft 1/2005

The role of gene expression profiling by microarray analysis for prognostic classification of breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

Methods for gene expression profiling in clinical trials for breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

Gene expression profile-based predictors of response to chemotherapy

01.05.2005 | Oral presentation | Sonderheft 1/2005

Present situation and future of genetic profiling for prognosis and treatment

01.05.2005 | Oral presentation | Sonderheft 1/2005

The role of magnetic resonance imaging as an imaging tool to assess disease status and residual disease in locally advanced breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

The roles of PET and CT/PET as preoperative studies

01.05.2005 | Oral presentation | Sonderheft 1/2005

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients

01.05.2005 | Oral presentation | Sonderheft 1/2005

Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

Simultaneous reconstructive surgery for radical mastectomy

01.05.2005 | Oral presentation | Sonderheft 1/2005

Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients

01.05.2005 | Oral presentation | Sonderheft 1/2005

Partial breast irradiation: why and how

01.05.2005 | Oral presentation | Sonderheft 1/2005

Simultaneous breast reconstruction

01.05.2005 | Oral presentation | Sonderheft 1/2005

Radiotherapy in early stage invasive breast cancer: current tendencies

01.05.2005 | Oral presentation | Sonderheft 1/2005

Chemoprevention: beyond tamoxifen

01.05.2005 | Oral presentation | Sonderheft 1/2005

Preoperative hormonal therapy: results and implications

01.05.2005 | Oral presentation | Sonderheft 1/2005

Primary chemotherapy for operable breast cancer: the NSABP experience

01.05.2005 | Oral presentation | Sonderheft 1/2005

Neoadjuvant treatment: the MD Anderson experience

01.05.2005 | Oral presentation | Sonderheft 1/2005

Tamoxifen resistance and adjuvant hormone therapy

01.05.2005 | Oral presentation | Sonderheft 1/2005

Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit

01.05.2005 | Oral presentation | Sonderheft 1/2005

Adjuvant chemotherapy for operable breast cancer: old vs new schema

01.05.2005 | Oral presentation | Sonderheft 1/2005

Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)

01.05.2005 | Oral presentation | Sonderheft 1/2005

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

01.05.2005 | Oral presentation | Sonderheft 1/2005

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma

01.05.2005 | Oral presentation | Sonderheft 1/2005

Oral vinorelbine in metastatic breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

The role of Xeloda in metastasic breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

Targeting the right chemotherapy for the right patient

01.05.2005 | Oral presentation | Sonderheft 1/2005

Role of translational studies in optimizing palliative chemotherapy

01.05.2005 | Oral presentation | Sonderheft 1/2005

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

01.05.2005 | Oral presentation | Sonderheft 1/2005

New agents for bone metastasis

01.05.2005 | Poster presentation | Sonderheft 1/2005

Cyclo-oxygenase-2 expression is associated with poor clinical outcome after doxorubicin-based chemotherapy in node-positive breast cancer: integration of tissue microarray

01.05.2005 | Poster presentation | Sonderheft 1/2005

Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node

01.05.2005 | Poster presentation | Sonderheft 1/2005

Fibroadenoma of breast in Iranian women between 1994 and 2004

01.05.2005 | Poster presentation | Sonderheft 1/2005

Nanoparticulate paclitaxel loaded into sterically stabilized mixed phospholipid micelles to improve chemotherapy of breast cancer

01.05.2005 | Poster presentation | Sonderheft 1/2005

6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone inhibits the growth of MCF-7 cells via inhibition of angiogenesis and hypoxia inducible factor alpha

01.05.2005 | Poster presentation | Sonderheft 1/2005

Clinical profile and management of bilateral breast cancer

01.05.2005 | Poster presentation | Sonderheft 1/2005

Adjuvant radiotherapy after surgery in breast cancer: evaluation of acute toxicity

01.05.2005 | Poster presentation | Sonderheft 1/2005

Breast cancer-screening programme amongst unpriviledged women in Charleroi (Hainaut), Belgium

01.05.2005 | Poster presentation | Sonderheft 1/2005

A performance study of different soft-computing procedures for automatic detection of breast cancer malignancy

01.05.2005 | Poster presentation | Sonderheft 1/2005

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

01.05.2005 | Poster presentation | Sonderheft 1/2005

The axillary study with ultrasound and cytological puncture with fine needle in invasive breast cancer.

01.05.2005 | Poster presentation | Sonderheft 1/2005

Expression of c-met gene in invasive ductal carcinomas

01.05.2005 | Poster presentation | Sonderheft 1/2005

[ASCRIT] Antisense chemoradioimmunotherapy consisting of anti-POEM (Arg-Gly-Asp) scFv linked onto high-energy radioisotopes, vinorelbine-tartrate and 21-nucleotide double-stranded siRNA targeted to DNMT1 induce apoptosis in metastatic breast cancer (MBC) characterized by hypermethylated p53, p16, RASSF1A, RAR-b2, BRCA2, H1C1, ESRI1, CDH1, Trbeta1, GSTP1, CCND2 and overexpression of bcl-2, cdc25c, Raf-1 and α8β1 integrin

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise